1. Genetic testing services: UWG provides genetic testing products and services, including individual genome testing, oncology gene testing, and hereditary disease testing. These testing services can provide individuals with genome-based health management and disease risk assessment, as well as individualized treatment plans for physicians. Genetic testing services are one of UWG's most profitable businesses.
2. Biomedical R&D Cooperation: UWG cooperates with pharmaceutical companies and scientific research institutes for biomedical R&D. UWGene can provide partners with gene sequencing, bioinformatics analysis, biological sample processing and other services to support collaborative projects in drug discovery, precision medicine and other fields. Revenue from these collaborative projects is also an important source of profit for UWG.
3. Sales of biochips and equipment: UWG manufactures and sells a variety of biochips and equipment, which are mainly used in gene sequencing, bioinformatics analysis and other fields. UWG's biochips and equipments are widely used worldwide, and the sales revenue is also an important part of its earnings.
4. Gene data services: UWM has accumulated a large amount of genomic data and clinical data, and can provide gene data analysis and interpretation services for academic research institutions, medical institutions and so on. These gene data services also generate some revenue for UWG.
Overall, UWG is profitable through a number of channels, including genetic testing services, biopharmaceutical R&D collaborations, biochip and device sales, and genetic data services. The combination of these businesses gives UWG a strong competitive edge in the genomic science and technology sector.